Bio-Techne (NASDAQ:TECH – Get Free Report) and Seer (NASDAQ:SEER – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Risk & Volatility
Bio-Techne has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
Earnings & Valuation
This table compares Bio-Techne and Seer”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Techne | $1.22 billion | 9.35 | $181.86 million | $1.15 | 63.00 |
| Seer | $16.58 million | 6.48 | -$73.60 million | ($1.22) | -1.59 |
Bio-Techne has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Bio-Techne and Seer, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Techne | 0 | 15 | 2 | 0 | 2.12 |
| Seer | 1 | 0 | 0 | 2 | 3.00 |
Bio-Techne presently has a consensus price target of $68.92, indicating a potential downside of 4.87%. Seer has a consensus price target of $4.00, indicating a potential upside of 106.19%. Given Seer’s stronger consensus rating and higher possible upside, analysts plainly believe Seer is more favorable than Bio-Techne.
Insider and Institutional Ownership
99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 11.3% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Bio-Techne and Seer’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Techne | 14.97% | 13.23% | 10.61% |
| Seer | -478.05% | -27.23% | -23.99% |
Summary
Bio-Techne beats Seer on 10 of the 15 factors compared between the two stocks.
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
About Seer
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
